Title:
Innovation in the biopharmaceutical industry
Innovation in the biopharmaceutical industry
| dc.contributor.advisor | Nair-Reichert, Usha | |
| dc.contributor.author | Kamada, Vitor | |
| dc.contributor.committeeMember | Kutlu, Levent | |
| dc.contributor.committeeMember | McCarthy, Patrick S. | |
| dc.contributor.committeeMember | Klimenko, Mikhail | |
| dc.contributor.committeeMember | Barke, Richard | |
| dc.contributor.department | Economics | |
| dc.date.accessioned | 2017-08-17T18:59:48Z | |
| dc.date.available | 2017-08-17T18:59:48Z | |
| dc.date.created | 2017-08 | |
| dc.date.issued | 2017-06-26 | |
| dc.date.submitted | August 2017 | |
| dc.date.updated | 2017-08-17T18:59:48Z | |
| dc.description.abstract | Three aspects of the drug development process are little understood in the literature: 1) which type of organization has comparative advantage in conducting clinical trials, firms or nonprofit organization (NPOs)?; 2) what determines the timing of technological collaboration?; and 3) how the strategies making, allying, and buying R&D impact the probability of drug approval? Using data on over 20,000 clinical trials, 800 technological alliances, and 14,000 R&D projects, the main findings of this econometric study are: 1) firms complete each phase of clinical trial faster than nonprofit organizations; 2) licensor scientific and technological specialization is the main factor to speed up the technological collaboration; and 3) R&D projects developed by research alliance have higher probability of drug approval than internal R&D projects, but R&D projects originated from M&A have lower probability of drug approval than internal R&D projects. Together these findings inform policy makers and managers on how to foster the innovation performance in the biopharmaceutical industry. | |
| dc.description.degree | Ph.D. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.uri | http://hdl.handle.net/1853/58684 | |
| dc.language.iso | en_US | |
| dc.publisher | Georgia Institute of Technology | |
| dc.subject | Innovation | |
| dc.subject | M&A | |
| dc.subject | Alliance | |
| dc.subject | Biopharmaceutical | |
| dc.subject | R&D | |
| dc.subject | Clinical trial | |
| dc.subject | Drug | |
| dc.subject | Technology | |
| dc.title | Innovation in the biopharmaceutical industry | |
| dc.type | Text | |
| dc.type.genre | Dissertation | |
| dspace.entity.type | Publication | |
| local.contributor.advisor | Nair-Reichert, Usha | |
| local.contributor.corporatename | School of Economics | |
| local.contributor.corporatename | Ivan Allen College of Liberal Arts | |
| relation.isAdvisorOfPublication | 627aaf4d-6abb-4f78-a52e-f170c6e26d3e | |
| relation.isOrgUnitOfPublication | 15802d30-e8cc-4b9a-86ef-2a59ac816e4b | |
| relation.isOrgUnitOfPublication | b1049ff1-5166-442c-9e14-ad804b064e38 | |
| thesis.degree.level | Doctoral |